Application of Virtual Histological Intravascular Ultrasound in Plaque Composition Assessment of Saphenous Vein Graft Diseases

0
0
0

Application of Virtual Histological Intravascular Ultrasound in Plaque Composition Assessment of Saphenous Vein Graft Diseases

Coronary artery bypass grafting (CABG) is a life-saving surgery for millions with severe coronary artery disease (CAD), but it comes with a hidden risk: saphenous vein graft disease (SVGD). Saphenous vein grafts (SVGs)—the most common conduits used in CABG—start losing patency within years: 93% are open at 1 year, but only 41% remain patent a decade later. This decline is driven by atherosclerosis, which turns once-healthy vein grafts into sites of narrowing, blockages, and increased risk of heart attacks or death. For patients with SVGD, percutaneous coronary intervention (PCI)—using stents to open blocked grafts—is the go-to treatment. Yet PCI itself carries risks: up to 15% of SVG-PCI procedures result in “no-reflow,” a dangerous condition where blood fails to flow through the treated vessel, doubling the risk of major adverse cardiac events (MACEs) like heart attacks or death.

The problem? Traditional imaging tools like gray-scale intravascular ultrasound (IVUS) can’t always see what’s inside SVG plaques—critical details that could predict no-reflow or guide safer treatment. Enter virtual histology-intravascular ultrasound (VH-IVUS), a game-changing technology that maps plaque composition in color, giving doctors a “virtual biopsy” of what’s happening in vein grafts.

What Is VH-IVUS, and Why Does It Matter?

Gray-scale IVUS uses sound waves to create black-and-white images of blood vessels, showing how much plaque blocks an artery. But it can’t distinguish between types of plaque—like fibrous tissue (stable) vs. a fatty, dead “necrotic core” (unstable). VH-IVUS solves this by analyzing the frequency of ultrasound echoes from different tissues. It then translates those signals into a color-coded map:

  • Fibrous tissue (FT): Stable, white plaque (most common in SVGs).
  • Fibro fatty (FF): Early fatty plaque (yellow).
  • Necrotic core (NC): A risky, fatty dead center (red).
  • Dense calcium (DC): Hard, calcified plaque (blue).

This level of detail is a game-changer. Studies show VH-IVUS is 91.7% sensitive and 96.6% specific at detecting necrotic cores—the same unstable plaques linked to heart attacks in native arteries. For SVGD, where plaques are often soft, fatty, and prone to rupture, VH-IVUS could be the key to predicting danger before it strikes.

What VH-IVUS Reveals About SVGD Plaques

SVGD is a dynamic process. Within a year of CABG, 10–25% of SVGs develop blood clots. By 2–5 years, necrotic cores form; by 5 years, intraluminal bleeding (from expanded necrotic cores) becomes common. By 7 years, SVG plaques look just like those in native coronary arteries—but with a twist: unlike native arteries (which often have heavy calcium), SVG plaques have sparse calcium in the vessel wall, not the plaque itself. Their necrotic cores are fatty and soft, with thin or absent fibrous caps—making them highly prone to rupture (break open) during PCI, triggering no-reflow.

VH-IVUS studies confirm these patterns. A 2010 study of 38 SVG patients found that plaque burden (how much of the artery is blocked) correlates strongly with fibrous fatty tissue (FF) and negatively with calcium. Lesions with >70% plaque burden had 2x more FF than less severe lesions. A 2019 Chinese study of high-risk SVG plaques—led by researchers at Tianjin Chest Hospital and Tianjin Medical University—went further:

  • Fibrous tissue (65%) was the main plaque component.
  • Necrotic core (12%) and fibro fatty tissue (3.8%) were common in high-risk plaques.
  • Graft age correlated with more FF: older grafts had larger FF areas.
  • Plaque burden (>70%) was linked to more FF and necrotic core—two markers of unstable plaque.

These findings matter because unstable plaques are the main cause of no-reflow during PCI. When a soft, fatty plaque ruptures, it releases debris that clogs tiny distal blood vessels, stopping blood flow. VH-IVUS lets doctors see these risky plaques before treatment—so they can take steps (like using embolic protection devices) to prevent disaster.

How VH-IVUS Could Transform SVG-PCI Care

For years, doctors relied on gray-scale IVUS to guess at plaque risk. But gray-scale IVUS misses small fatty plaques (only 24% sensitive) and can’t tell fibrous from fibrous fatty tissue. VH-IVUS fills that gap. Studies in native arteries show VH-IVUS-detected necrotic cores and thin-cap fibroatheromas (TCFAs—plaques with a thin fibrous cap over a large necrotic core) predict no-reflow and MACEs. For example:

  • The PROSPECT study (a landmark trial of 697 CAD patients) found that plaque burden >70%, minimum luminal area <4 mm², and VH-IVUS TCFA were independent predictors of future heart attacks from non-culprit lesions.
  • The VIVA study linked VH-IVUS TCFA to higher rates of MACEs, even in non-stenotic (mildly blocked) arteries.

For SVGD, the logic is the same: if a vein graft has a large necrotic core or TCFA, it’s more likely to rupture during PCI, causing no-reflow. VH-IVUS could help doctors:

  1. Risk-stratify patients: Identify who’s most likely to have no-reflow.
  2. Choose treatment: Use embolic protection devices or drug-eluting stents for high-risk plaques.
  3. Improve outcomes: Reduce MACEs by targeting unstable plaques early.

What’s Next for VH-IVUS and SVGD?

While VH-IVUS shows promise, there’s still much to learn. Most studies on SVG plaques are small or cross-sectional (looking at one point in time). We need larger, multicenter trials with long-term follow-up to answer key questions:

  • Do VH-IVUS-detected plaque components (like necrotic core size) directly predict MACEs in SVGD patients?
  • Can VH-IVUS-guided treatment (e.g., using embolic protection for large necrotic cores) reduce no-reflow rates?
  • How do SVG plaques change over time, and can VH-IVUS track that progression?

These studies could turn VH-IVUS from a research tool into a standard part of SVG-PCI care—helping doctors save more lives.

Conclusion

Saphenous vein graft disease is a silent threat to CABG patients, but VH-IVUS is changing the game. By mapping plaque composition in vivid color, this technology lets doctors see what was once invisible: the fatty, unstable cores that cause no-reflow and MACEs. The 2019 study from Tianjin Chest Hospital and Tianjin Medical University adds critical data to the field, showing how VH-IVUS can identify high-risk SVG plaques. While more research is needed, VH-IVUS has the potential to make SVG-PCI safer and more effective—giving CABG patients a better shot at long-term health.

doi.org/10.1097/CM9.0000000000000183

Was this helpful?

0 / 0